Another Go At Certican: Novartis Transplant Agent To Go To Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Dec. 7 meeting marks the third review cycle for the transplant indication for everolimus, which previously received two "approvable" letters.
You may also be interested in...
Far From Certican: Novartis Hopes REMS Will Tip Balance For Kidney Transplant Drug
FDA's cardio-renal committee will weigh whether a communication-focused risk management plan can assuage concerns about renal toxicity and slow wound healing.
Far From Certican: Novartis Hopes REMS Will Tip Balance For Kidney Transplant Drug
FDA's cardio-renal committee will weigh whether a communication-focused risk management plan can assuage concerns about renal toxicity and slow wound healing.
Afinitor Wins FDA Nod For Kidney Cancer
The mTor inhibitor targets Sutent or Nexavar treatment failures.